Edenred Shares Climb Nearly 3%, Marking a Third Month of Gains

Morgan Stanley Raises Target to €34, Fueling Today's Movement

Edenred shares are up 2.81% at €25.58 during the session, leading the SBF 120. The stock benefits from the latest Morgan Stanley review, which upgrades to 'overweight' with a target set at €34, representing a potential of nearly 33% above the current price. The recovery that began several weeks ago is accompanied by a significant reduction in short bets: according to collected statements, six funds cumulatively hold 4.82% of the capital sold short, down from 8.88% a month ago (-4.06 points in thirty days). This decline reflects a gradual covering of short positions, without completely erasing the skepticism accumulated earlier in the year. The movement remains to be monitored over time, as the stock has already experienced significant volatility since the acquisition rumors in June.

Stock Remains Above Its Three Moving Averages, RSI at 66

In terms of indicators, today's rise further widens the already significant gap to the moving averages: the price is 10.83% above the MM20 (€23.08) and nearly 27% above the MM200 (€20.12). An RSI at 66 indicates a sustained buying momentum, without yet tipping into overbought territory. The progress reaches 23.16% over one month and 37.05% over three months, an acceleration that brings the stock closer to its identified resistance at €27.20. Conversely, the performance over one year remains slightly negative (-1.99%), recalling the magnitude of the correction suffered at the end of 2025. The potential crossing of €27.20 will be the next technical milestone to observe in the case.